ReviewFrontiers in immunology2023
Protein modification by short-chain fatty acid metabolites in sepsis: a comprehensive review.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 14 citations in OpenAlex.
- Therapeutic Remodeling of the Gut Microbiome as a Strategy to Restore Immune Tolerance in Autoimmunity.MicrobiologyOpen · 2026Review
- Gut microbiota dysbiosis in sepsis: mechanisms and the gut-organ axis with a focus on lung and brain interactions.Frontiers in microbiology · 2026Review
- Gut microbiota and sepsis-associated acute kidney injury: a narrative review.Frontiers in immunology · 2026Review
- The immunology of sepsis: translating new insights into clinical practice.Nature reviews. Nephrology · 2026Review
- Immunometabolic reprogramming in sepsis: mechanisms, clinical endotypes, and therapeutic opportunities.Frontiers in immunology · 2026Review
- Metabolic and post-translational modifications in sepsis-associated immune dysfunction: a conceptual framework.Frontiers in immunology · 2026Review
- Article
- Microbial profile of the appendix niche in acute appendicitis: a novel sampling approach.FEBS open bio · 2025Article
- Identifying propionate metabolism-related genes as biomarkers of sepsis development and therapeutic targets.Scientific reports · 2025Article
- The emerging role of microbiota derived SCFAs in neurodegenerative disorders.Brain, behavior, & immunity - health · 2025Review
- Metabolic reprogramming tailors T cell immunity in sepsis.Frontiers in immunology · 2025Review
- Role of novel protein acylation modifications in sepsis.Frontiers in immunology · 2025Review
- Gut-lung immunometabolic crosstalk in sepsis: from microbiota to respiratory failure.Frontiers in medicine · 2025Review
- Gut microbiota: a promising new target in immune tolerance.Frontiers in immunology · 2025Review
- Multi-omics decodes host-specific and environmental microbiome interactions in sepsis.Frontiers in microbiology · 2025Review
- The progress of the microbe-gut-brain axis in sepsis-associated encephalopathy.Frontiers in cellular and infection microbiology · 2025Review
- Effect of inulin from dahlia tubers (BioMedicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is a major life-threatening syndrome of organ dysfunction caused by a dysregulated host response due to infection. Dysregulated immunometabolism is fundamental to the onset of sepsis. Particularly, short-chain fatty acids (SCFAs) are gut microbes derived metabolites serving to drive the communication between gut microbes and the immune system, thereby exerting a profound influence on the pathophysiology of sepsis. Protein post-translational modifications (PTMs) have emerged as key players in shaping protein function, offering novel insights into the intricate connections between metabolism and phenotype regulation that characterize sepsis. Accumulating evidence from recent studies suggests that SCFAs can mediate various PTM-dependent mechanisms, modulating protein activity and influencing cellular signaling events in sepsis. This comprehensive review discusses the roles of SCFAs metabolism in sepsis associated inflammatory and immunosuppressive disorders while highlights recent advancements in SCFAs-mediated lysine acylation modifications, such as substrate supplement and enzyme regulation, which may provide new pharmacological targets for the treatment of sepsis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.